Background Background Weight gain is a common
Weight gain is a common consequence of antipsychotic drug consequence of antipsychotic drug treatment and can lead to further treatment and can lead to further morbidity. morbidity.
Aims Aims To assess the effects of
To assess the effects of antipsychotic drug therapy on abdominal antipsychotic drug therapy on abdominal fat deposition, on insulin and leptin fat deposition, on insulin and leptin secretion, and on circulating glucose and secretion, and on circulating glucose and lipids. lipids.
Method Method Abdominal body fat was
Abdominal body fat was determined by magnetic resonance determined by magnetic resonance imaging in a group of previously untreated imaging in a group of previously untreated patients with schizophrenia, before and patients with schizophrenia, before and after10 weeks'antipsychotic drug after10 weeks'antipsychotic drug treatment.Body mass and blood treatment.Body mass and blood concentrations of glucose, insulin, leptin concentrations of glucose, insulin, leptin and lipids were also measured. and lipids were also measured.
Results

Results Significant increases in both
Significant increases in both subcutaneous and intra-abdominal fat subcutaneous and intra-abdominal fat were identified after antipsychotic drug were identified after antipsychotic drug treatment. Athree-fold increase in leptin treatment. Athree-fold increase in leptin secretion as well as significant increases in secretion as well as significant increases in levels of circulating lipids and non-fasting levels of circulating lipids and non-fasting glucose were also identified. glucose were also identified.
Conclusions Conclusions Patients first receiving
Patients first receiving antipsychotic drugs experience substantial antipsychotic drugs experience substantial deposition of both subcutaneous and deposition of both subcutaneous and intra-abdominal fat, reflecting a loss of the intra-abdominal fat, reflecting a loss of the normalinhibitory control of leptin on body normalinhibitory control of leptin on body mass. Along with fat deposition, the mass. Along with fat deposition, the increase in levels of fasting lipids and in increase in levels of fasting lipids and in non-fasting glucose may provide early non-fasting glucose may provide early signs of drug-induced progression towards signs of drug-induced progression towards the metabolic syndrome. the metabolic syndrome.
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Weight gain is a major side-effect of antiWeight gain is a major side-effect of antipsychotic drug treatment, contributing to psychotic drug treatment, contributing to morbidity and poor adherence to treatmorbidity and poor adherence to treatment. Several of the newer atypical antiment. Several of the newer atypical antipsychotic agents have profound effects on psychotic agents have profound effects on weight, the greatest increases occurring weight, the greatest increases occurring with clozapine and olanzapine (Allison with clozapine and olanzapine (Allison et al et al, 1999) . Obesity has its inevitable con-, 1999) . Obesity has its inevitable consequences, which are increasingly observed sequences, which are increasingly observed in patients receiving antipsychotic drugs; in patients receiving antipsychotic drugs; such consequences may include the 'metasuch consequences may include the 'metabolic syndrome' of hypertension, cardiobolic syndrome' of hypertension, cardiovascular disease, dyslipidaemia and vascular disease, dyslipidaemia and impaired glucose tolerance, which may lead impaired glucose tolerance, which may lead to type 2 diabetes (Henderson, 2002;  to type 2 diabetes (Henderson, 2002; Koponen Koponen et al et al, 2002) . This study aims to , 2002). This study aims to explore the effect of initial antipsychotic explore the effect of initial antipsychotic drug treatment on abdominal fat deposidrug treatment on abdominal fat deposition, and how this increase in body fat tion, and how this increase in body fat relates to circulating leptin, insulin and relates to circulating leptin, insulin and lipid levels in drug-naıve patients with lipid levels in drug-naïve patients with first-episode schizophrenia. first-episode schizophrenia.
METHOD METHOD
Study sample Study sample
Participants in the study were in-patients of Participants in the study were in-patients of Chinese Han ethnicity referred to the Chinese Han ethnicity referred to the Department of Psychiatry, Nanjing Brain Department of Psychiatry, Nanjing Brain Hospital and Nanjing Medical University, Hospital and Nanjing Medical University, China. All patients met the criteria for a China. All patients met the criteria for a diagnosis of schizophrenia according to diagnosis of schizophrenia according to DSM-IV (American Psychiatric Associa-DSM-IV (American Psychiatric Association, 1994). These people were experiention, 1994). These people were experiencing their first psychotic episode and had cing their first psychotic episode and had not previously received antipsychotic drug not previously received antipsychotic drug treatment. They had no other mental and treatment. They had no other mental and neurological disease, eating disorder, neurological disease, eating disorder, diabetes mellitus, hypertension, or history diabetes mellitus, hypertension, or history of alcohol or other substance misuse. Antiof alcohol or other substance misuse. Antipsychotic treatment was not randomised psychotic treatment was not randomised but provided according to normal local but provided according to normal local clinical practice for 10 weeks. This involved clinical practice for 10 weeks. This involved treatment primarily with risperidone or treatment primarily with risperidone or chlorpromazine; diazepam, or antichochlorpromazine; diazepam, or anticholinergic drugs to control extrapyramidal linergic drugs to control extrapyramidal side-effects were administered as required. side-effects were administered as required.
All participants gave written informed All participants gave written informed consent for participation in the study, consent for participation in the study, which had been approved by the hospital's which had been approved by the hospital's ethics committee, in accordance with the ethics committee, in accordance with the Declaration of Helsinki. Declaration of Helsinki.
A total of 46 patients were recruited (27 A total of 46 patients were recruited (27 men and 19 women). All patients received men and 19 women). All patients received dietetically balanced hospital meals (daily dietetically balanced hospital meals (daily energy intake: men 10.5 MJ (2500 kcal), energy intake: men 10.5 MJ (2500 kcal), women 9.2 MJ (2200 kcal)), occasionally women 9.2 MJ (2200 kcal)), occasionally supplemented by gifts from relatives, and supplemented by gifts from relatives, and had the opportunity for an hour's physical had the opportunity for an hour's physical exercise each day. All patients were rated exercise each day. All patients were rated using the Positive and Negative Syndrome using the Positive and Negative Syndrome Scale (PANSS; Kay Scale (PANSS; Kay et al et al, 1987) 
Control group Control group
The control group consisted of hospital The control group consisted of hospital staff well matched for age (26.9 years, staff well matched for age (26.9 years, s.d. s.d.¼50) and gender (22 men, 16 women) 50) and gender (22 men, 16 women) with the patient group, and were all apparwith the patient group, and were all apparently healthy after assessment by physical ently healthy after assessment by physical examination, blood screening and urine examination, blood screening and urine test. None had any history of treatment test. None had any history of treatment for neuropsychiatric disorders. for neuropsychiatric disorders.
Experimental measures Experimental measures
Body fat indicators Body fat indicators
Weight, height, and waist and hip circumWeight, height, and waist and hip circumferences were measured, and the body mass ferences were measured, and the body mass index (BMI) and waist:hip ratio (WHR) index (BMI) and waist:hip ratio (WHR) were calculated for all patients on admiswere calculated for all patients on admission and weekly for 10 weeks. The same sion and weekly for 10 weeks. The same measurements were made on the control measurements were made on the control group members. Waist circumference was group members. Waist circumference was measured midway between the lower rib measured midway between the lower rib margin and the iliac crest, and hip circummargin and the iliac crest, and hip circumference was measured at the level of the ference was measured at the level of the widest circumference. Measurement of widest circumference. Measurement of abdominal subcutaneous fat (SUB) and abdominal subcutaneous fat (SUB) and intra-abdominal fat (IAF; visceral fat) was intra-abdominal fat (IAF; visceral fat) was performed by magnetic resonance imaging performed by magnetic resonance imaging (MRI) on subgroups of participants (40 (MRI) on subgroups of participants (40 patients and 22 controls) with a wholepatients and 22 controls) with a wholebody scanner (Siemens Magnetom 8) using body scanner (Siemens Magnetom 8) using a 0.2 T magnetic field and an inversion a 0.2 T magnetic field and an inversion recovery pulse sequence (inversion time recovery pulse sequence (inversion time 0.25 ms, repetition time 500 ms, and echo 0.25 ms, repetition time 500 ms, and echo time 20 ms; field of view 380 mm time 20 ms; field of view 380 mm (1990) . Scans were taken within 36 h (1990). Scans were taken within 36 h of admission and after 10 weeks. of admission and after 10 weeks.
Biochemical indicators Biochemical indicators
Blood was taken for testing from the Blood was taken for testing from the patients on admission and after 10 weeks patients on admission and after 10 weeks of antipsychotic treatment. Whole venous of antipsychotic treatment. Whole venous blood samples were taken into tubes blood samples were taken into tubes containing ethylenediamine tetra-acetic containing ethylenediamine tetra-acetic acid (EDTA) at approximately 06.30 h acid (EDTA) at approximately 06.30 h following overnight fasting, and 2 h after following overnight fasting, and 2 h after breakfast for non-fasting plasma glucose breakfast for non-fasting plasma glucose measurement. After centrifugation at measurement. After centrifugation at 2500 g at 4 2500 g at 4 8 8C for 5 min, plasma super-C for 5 min, plasma supernatants were collected and immediately natants were collected and immediately stored at stored at 7 780 80 8 8C prior to assay. The sam-C prior to assay. The samples were processed randomly and masked ples were processed randomly and masked to diagnosis. Plasma glucose concentration to diagnosis. Plasma glucose concentration was assayed by an automated glucose was assayed by an automated glucose oxidase method. Measures of lipids -total oxidase method. Measures of lipids -total high-density lipoprotein (HDL) and lowhigh-density lipoprotein (HDL) and lowdensity lipoprotein (LDL) cholesterol and density lipoprotein (LDL) cholesterol and triglycerides -were determined by standtriglycerides -were determined by standard clinical biochemistry laboratory assays. ard clinical biochemistry laboratory assays. Fasting plasma insulin was measured Fasting plasma insulin was measured with a with a 125 125 I-insulin radioimmunoassay kit I-insulin radioimmunoassay kit (National Health Institute, Beijing, China) (National Health Institute, Beijing, China) in duplicate for each participant. The intrain duplicate for each participant. The intraand interassay coefficients of variation were and interassay coefficients of variation were below 3%. A leptin immunoradiometric kit below 3%. A leptin immunoradiometric kit (ACTIVE Human Leptin Coated-Tube (ACTIVE Human Leptin Coated-Tube Immunoradiometric Assay Kit DSLImmunoradiometric Assay Kit DSL-23100, Diagnostic Systems Laboratories, 23100, Diagnostic Systems Laboratories, Webster, TX, USA) was used to determine Webster, TX, USA) was used to determine total fasting plasma leptin levels in duplitotal fasting plasma leptin levels in duplicate. The intra-and interassay coefficients cate. The intra-and interassay coefficients of variation were below 4%. of variation were below 4%.
Data analysis Data analysis
All statistical analyses were performed using All statistical analyses were performed using the Statistical Package for the Social the Statistical Package for the Social Sciences, version 10.0. Initial analysis Sciences, version 10.0. Initial analysis involved univariate analysis of variance involved univariate analysis of variance (ANOVA) to compare the study groups, (ANOVA) to compare the study groups, and repeated-measures analysis to determine and repeated-measures analysis to determine the effects of treatment on body fat and the effects of treatment on body fat and biochemical indicators. Except where signifbiochemical indicators. Except where significant interaction terms were observed, the icant interaction terms were observed, the results are reported as results are reported as t t-tests. Values are -tests. Values are given as mean (standard deviation). Signifigiven as mean (standard deviation). Significance levels are for two-tailed tests; cance levels are for two-tailed tests; P P values below 0.05 were regarded as values below 0.05 were regarded as significant. Antipsychotic dose was consignificant. Antipsychotic dose was converted to chlorpromazine equivalents (risverted to chlorpromazine equivalents (risperidone dose peridone dose6 6100). Correlations between 100). Correlations between biochemical indicators and clinical parabiochemical indicators and clinical parameters and features were examined by meters and features were examined by Spearman rank correlation. Stepwise multiSpearman rank correlation. Stepwise multiple regression was used for analysis of the ple regression was used for analysis of the influence of weight and fat indicators and influence of weight and fat indicators and clinical features on plasma leptin levels. clinical features on plasma leptin levels.
RESULTS RESULTS
Patient treatment and clinical Patient treatment and clinical response response
The age, treatment details and symptom The age, treatment details and symptom scores for the patient groups are shown in scores for the patient groups are shown in Table 1 . There was no significant difference Table 1 . There was no significant difference between male and female patients in age or between male and female patients in age or symptom score at baseline and after treatsymptom score at baseline and after treatment (all ment (all P P4 40.05, data not shown). Thirty 0.05, data not shown). Thirty patients received risperidone at an initial patients received risperidone at an initial daily dose of 1 mg, increasing over 10 days daily dose of 1 mg, increasing over 10 days to a mean dose of 4.77 mg (s. P¼0.019). 0.019). There were significant increases in all There were significant increases in all weight and fat indicators after 10 weeks' weight and fat indicators after 10 weeks' antipsychotic treatment in the patient antipsychotic treatment in the patient group (Table 2 ). This showed significant group (Table 2) . This showed significant interactions with gender for SUB interactions with gender for SUB ( (F F¼5.675, 5.675, P P¼0.022), and particularly for 0.022), and particularly for IAF ( IAF (F F¼13.727, 13.727, P P¼0.001) and WHR 0.001) and WHR ( (F F¼11.574, 11.574, P P¼0.001), but not for BMI, re-0.001), but not for BMI, reflecting substantially greater changes in the flecting substantially greater changes in the male group than in the female group. Thus male group than in the female group. Thus no significant change in WHR and SUB was no significant change in WHR and SUB was apparent for the female patients after treatapparent for the female patients after treatment; significant differences between males ment; significant differences between males and females were found for the changes in and females were found for the changes in WHR ( WHR (t t¼3.496, 3.496, P P¼0.001), SUB ( 0.001), SUB (t t¼2.2, 2.2, P P¼0.038) and IAF ( 0.038) and IAF (t t¼3.941, 3.941, P P¼0.0001). 0.0001). P¼0.049). 0.049). There was a substantial elevation in There was a substantial elevation in plasma leptin in the patient group after 10 plasma leptin in the patient group after 10 weeks' treatment as well as within gender weeks' treatment as well as within gender subgroups (Table 3) . No significant differsubgroups (Table 3) . No significant difference in plasma insulin was found after 10 ence in plasma insulin was found after 10 weeks of treatment. There was no signifiweeks of treatment. There was no significant difference in fasting plasma glucose cant difference in fasting plasma glucose levels before and after treatment either in levels before and after treatment either in all patients or in the gender subgroups. all patients or in the gender subgroups. However, after 10 weeks of treatment, a However, after 10 weeks of treatment, a significant increase in non-fasting plasma significant increase in non-fasting plasma glucose concentration was found. Subglucose concentration was found. Substantial and significant differences were stantial and significant differences were also observed in total and LDL cholesterol also observed in total and LDL cholesterol 5 9 5 9 Within the MRI-determined baseline body Within the MRI-determined baseline body fat indicators, only IAF was positively corfat indicators, only IAF was positively correlated with age ( related with age (r r¼0.463, 0.463, P P¼0.003) in 0.003) in the patient group but not significantly in the patient group but not significantly in the control group ( the control group (r r¼0.201, 0.201, P P¼0.37). 0.37). There was no significant correlation beThere was no significant correlation between the changes in body fat and clinical tween the changes in body fat and clinical features, including age and antipsychotic features, including age and antipsychotic dose. The biochemical markers also showed dose. The biochemical markers also showed no significant correlation with these clinical no significant correlation with these clinical features (data not shown). Patients showed features (data not shown). Patients showed a substantial decrease in PANSS scores a substantial decrease in PANSS scores over 10 weeks' treatment (see Table 1 ); over 10 weeks' treatment (see Table 1 ); however, the change in BMI was not however, the change in BMI was not significantly correlated with this clinical significantly correlated with this clinical improvement ( improvement (r r¼0.223, 0.223, P P¼0.137). 0.137). In the control group there was no sigIn the control group there was no significant relationship between plasma leptin nificant relationship between plasma leptin levels and body fat, although a trend to levels and body fat, although a trend to increased SUB with increased leptin was increased SUB with increased leptin was apparent ( apparent (r r¼0.384, 0.384, P P¼0.078). In patients, 0.078). In patients, initial leptin concentrations correlated siginitial leptin concentrations correlated significantly with BMI at baseline ( nificantly with BMI at baseline (r r¼0.33, 0.33, P P¼0.03), and with SUB but not IAF mea-0.03), and with SUB but not IAF measurements at baseline ( surements at baseline (r r¼0.73, 0.73, P P¼0.0001). 0.0001). Leptin, both on admission and after 10 Leptin, both on admission and after 10 weeks, correlated inversely with the percenweeks, correlated inversely with the percentage change in SUB ( tage change in SUB (r r¼7 70.505, 0.505, P P¼0.002; 0.002; r r¼7 70.467, 0.467, P P¼0.005) but not with that in 0.005) but not with that in IAF. Moreover, this change in SUB but IAF. Moreover, this change in SUB but not in IAF was also strongly correlated with not in IAF was also strongly correlated with fasting insulin concentrations at base fasting insulin concentrations at baseline line 6 0 6 0 ( (r r¼7 70.523, 0.523, P P¼0.001) and after 10 weeks' 0.001) and after 10 weeks' treatment ( treatment (r r¼7 70.537, 0.537, P P¼0.001). To 0.001). To elucidate further the influences on plasma elucidate further the influences on plasma leptin in schizophrenia, stepwise multiple leptin in schizophrenia, stepwise multiple regression was performed with body fat inregression was performed with body fat indicators, gender, age, drug type and antidicators, gender, age, drug type and antipsychotic dose included as independent psychotic dose included as independent variables; only gender and baseline SUB variables; only gender and baseline SUB were significantly associated with initial were significantly associated with initial leptin ( leptin (b b¼7 70.64, 0.64, t t¼4.928, 4.928, P P¼0.0001), 0.0001), whereas after 10 weeks leptin was only whereas after 10 weeks leptin was only significantly related to gender. significantly related to gender.
Biochemical indicators Biochemical indicators
DISCUSSION DISCUSSION
Weight gain and fat deposition Weight gain and fat deposition in the treatment of schizophrenia in the treatment of schizophrenia To our knowledge, this is the first investiTo our knowledge, this is the first investigation into the initial effects on weight gation into the initial effects on weight and regional fat distribution measured and regional fat distribution measured by MRI following antipsychotic treatby MRI following antipsychotic treatment of patients with a first episode of ment of patients with a first episode of schizophrenia. The MRI technique is a schizophrenia. The MRI technique is a precise and reliable means of determining precise and reliable means of determining the two fat measures, with better resoluthe two fat measures, with better resolution tion than computed tomography (CT) than computed tomography (CT) (Seidell (Seidell et al et al, 1990) . We obtained no sub-, 1990). We obtained no substantial evidence of a difference in weight stantial evidence of a difference in weight or fat deposition between the control group or fat deposition between the control group and the patient group, although slight eleand the patient group, although slight elevations in fat indicators (despite lower vations in fat indicators (despite lower mean BMI values) were apparent in the mean BMI values) were apparent in the patients in comparison with control participatients in comparison with control participants. This is in contrast to the findings of pants. This is in contrast to the findings of Thakore Thakore et al et al (2002) , who reported that (2002), who reported that IAF but not SUB (determined by CT) was IAF but not SUB (determined by CT) was significantly increased in patients with significantly increased in patients with schizophrenia compared with age-matched schizophrenia compared with age-matched normal controls, and that this was unrenormal controls, and that this was unrelated to antipsychotic drug treatment. lated to antipsychotic drug treatment. However, differences in social factors However, differences in social factors between Thakore's sample of patients and between Thakore's sample of patients and the Chinese patients investigated here, as the Chinese patients investigated here, as well as the presence of previously treated well as the presence of previously treated drug-free patients in the former study, drug-free patients in the former study, might have contributed to the apparent might have contributed to the apparent discrepancy with the results presented here. discrepancy with the results presented here.
It is well established that antipsychotic It is well established that antipsychotic drug treatment can induce substantial drug treatment can induce substantial weight gain, with different drugs having weight gain, with different drugs having greater or lesser effects, and the greatest greater or lesser effects, and the greatest increases occurring with atypical antipsyincreases occurring with atypical antipsychotics (reviewed by Allison chotics (reviewed by Allison et al et al, 1999; , 1999; Taylor & McAskill, 2000) . Inevitably, Taylor & McAskill, 2000) . Inevitably, most studies undertaken in the context of most studies undertaken in the context of drug trials have assessed patients who had drug trials have assessed patients who had previously received antipsychotic drug previously received antipsychotic drug treatment. Such treatment confounds the treatment. Such treatment confounds the effects of drugs over the period of the study effects of drugs over the period of the study by elevating values of baseline weight and by elevating values of baseline weight and related metabolic measures by amounts related metabolic measures by amounts dependent on the drug (or drugs) previously dependent on the drug (or drugs) previously received. In addition, the difficulty in received. In addition, the difficulty in distinguishing correlates of disease from distinguishing correlates of disease from the consequences of drug treatment means the consequences of drug treatment means that it is possible that schizophrenia itself that it is possible that schizophrenia itself can be a risk factor for the metabolic syncan be a risk factor for the metabolic syndrome (Ryan & Thakore, 2002) . Hence drome (Ryan & Thakore, 2002) . Hence the importance of studies in drug-naıve the importance of studies in drug-naïve patients. We observed that initial antipatients. We observed that initial antipsychotic treatment has a substantial effect psychotic treatment has a substantial effect on weight and fat deposition. on weight and fat deposition.
The mechanisms underlying this The mechanisms underlying this antipsychotic-drug induced weight gain antipsychotic-drug induced weight gain are likely to be multifactorial. Antagonism are likely to be multifactorial. Antagonism of the serotonin receptor 5-HT of the serotonin receptor 5-HT 2C 2C , for , for which several antipsychotic drugs, partiwhich several antipsychotic drugs, particularly olanzapine and clozapine, have cularly olanzapine and clozapine, have high affinity, is a strong candidate as the high affinity, is a strong candidate as the receptor is known to influence appetite receptor is known to influence appetite and thereby weight gain (Nonogaki and thereby weight gain (Nonogaki et et al al, 1998) . Association of a polymorphism , 1998). Association of a polymorphism of the 5-HT of the 5-HT 2C 2C receptor gene with antireceptor gene with antipsychotic drug-induced weight gain propsychotic drug-induced weight gain provides further evidence of the importance vides further evidence of the importance of the receptor in this process (Reynolds of the receptor in this process (Reynolds et al et al, 2002 
Leptin changes Leptin changes
Leptin is a hormone secreted by adipose Leptin is a hormone secreted by adipose tissue to have effects at receptors in the tissue to have effects at receptors in the hypothalamus that result in the control of hypothalamus that result in the control of food intake. Deficits in leptin or leptin food intake. Deficits in leptin or leptin receptors result in overeating and obesity, receptors result in overeating and obesity, indicating the importance of the hormone indicating the importance of the hormone in body mass homoeostasis. The increase in body mass homoeostasis. The increase in fat deposition observed here occurred in fat deposition observed here occurred despite a substantial elevation in levels of despite a substantial elevation in levels of circulating leptin, indicating that leptin circulating leptin, indicating that leptin control of fat deposition in patients receivcontrol of fat deposition in patients receiving antipsychotic treatment is awry. This ing antipsychotic treatment is awry. This is likely to occur because the drugs block is likely to occur because the drugs block other receptors, e.g. 5-HT other receptors, e.g. 5-HT 2C 2C , that interact , that interact with the effects of leptin in the hypothalawith the effects of leptin in the hypothalamus (Nonogaki mus (Nonogaki et al et al, 1998) . However, the , 1998). However, the inverse correlation between SUB increases inverse correlation between SUB increases and leptin levels suggests that some and leptin levels suggests that some remaining influence of leptin on subremaining influence of leptin on subcutaneous fat deposition is present. These cutaneous fat deposition is present. These results are certainly consistent with preresults are certainly consistent with previous findings of elevated leptin concenvious findings of elevated leptin concentrations in antipsychotic-treated patients trations in antipsychotic-treated patients with schizophrenia (Herran with schizophrenia (Herran et al et al, 2001) , 2001) and appear likely to be a consequence of and appear likely to be a consequence of subcutaneous fat deposition, over which subcutaneous fat deposition, over which leptin normally imparts most regulatory leptin normally imparts most regulatory control (Cnop control (Cnop et al et al, 2002) . , 2002).
Weight gain and hyperglycaemia Weight gain and hyperglycaemia
The accumulation of intra-abdominal fat The accumulation of intra-abdominal fat seen in patients in this study may well be seen in patients in this study may well be the first indication of increasing risk of the first indication of increasing risk of diabetes, since this measure is correlated diabetes, since this measure is correlated with insulin resistance (Cnop with insulin resistance (Cnop et al et al, 2002) . , 2002). Certainly there is growing evidence that Certainly there is growing evidence that the treatment of schizophrenia, particularly the treatment of schizophrenia, particularly with clozapine and olanzapine, may impair with clozapine and olanzapine, may impair glucose metabolism and increase the risk of glucose metabolism and increase the risk of diabetes (Henderson, 2002; Newcomer diabetes (Henderson, 2002; Newcomer et et al al, 2002) . We observed that an increase in , 2002). We observed that an increase in non-fasting glucose concentration emerged non-fasting glucose concentration emerged after 10 weeks' treatment. This finding after 10 weeks' treatment. This finding may provide the first indications of may provide the first indications of impaired glucose utilisation, which has impaired glucose utilisation, which has been reported in patients treated chronibeen reported in patients treated chronically with risperidone, as well as more procally with risperidone, as well as more profound effects following olanzapine and found effects following olanzapine and clozapine (Newcomer clozapine (Newcomer et al et al, 2002) . More , 2002). More speculatively, this developing insulin resisspeculatively, this developing insulin resistance, along with the observations of tance, along with the observations of central fat deposition and the substantial central fat deposition and the substantial and significant increases in blood lipid and significant increases in blood lipid levels, may reflect early signs of progression levels, may reflect early signs of progression towards the metabolic syndrome. towards the metabolic syndrome.
Drug-induced weight gain Drug-induced weight gain and clinical improvement and clinical improvement
The changes in weight and/or body fat The changes in weight and/or body fat indicators do not appear to be related to indicators do not appear to be related to clinical improvement in this study. Our clinical improvement in this study. Our finding is consistent with the absence finding is consistent with the absence of any significant relationship between of any significant relationship between weight gain and symptom improvement in weight gain and symptom improvement in another, larger, sample of similar patients another, larger, sample of similar patients (Zhang (Zhang et al et al, 2003) , despite reports that , 2003), despite reports that weight gain is positively correlated with weight gain is positively correlated with symptom improvement following clozapine symptom improvement following clozapine and olanzapine (Czobor and olanzapine (Czobor et al et al, 2002) . How-, 2002) . However, consistent with our findings, the latter ever, consistent with our findings, the latter report found no relationship between report found no relationship between weight gain and symptom improvement in weight gain and symptom improvement in patients receiving risperidone. In addition, patients receiving risperidone. In addition, it is difficult to eliminate artefactual results it is difficult to eliminate artefactual results from such studies; poor nutrition and low from such studies; poor nutrition and low weight may be a consequence of more weight may be a consequence of more severe symptoms, and such patients may severe symptoms, and such patients may show greater increases in both symptom show greater increases in both symptom improvement and weight gain following improvement and weight gain following treatment. treatment.
Although the findings reported here Although the findings reported here describe the consequences of just 10 weeks' describe the consequences of just 10 weeks' treatment with common antipsychotics, treatment with common antipsychotics, they do provide indicators of a developing they do provide indicators of a developing morbidity associated with weight gain. morbidity associated with weight gain. Such studies need to be extended to deterSuch studies need to be extended to determine the longer-term consequences of antimine the longer-term consequences of antipsychotic drug treatment in previously psychotic drug treatment in previously drug-naıve patients, and to differentiate drug-naïve patients, and to differentiate better the effects of different drugs. Howbetter the effects of different drugs. However, the potential that substantial subcutaever, the potential that substantial subcutaneous and visceral fat deposits (particularly neous and visceral fat deposits (particularly the latter) may have in developing insulin the latter) may have in developing insulin resistance leading to the metabolic resistance leading to the metabolic syndrome suggests that all should be done syndrome suggests that all should be done to minimise this drug-induced weight gain to minimise this drug-induced weight gain and its impact. This may include dietary and its impact. This may include dietary counselling (Meltzer, 2001) , routine screencounselling (Meltzer, 2001) , routine screening for diabetes (Henderson, 2002) or even, ing for diabetes (Henderson, 2002) or even, in the future, genetic testing for liability in the future, genetic testing for liability (Reynolds (Reynolds et al et al, 2002 This effect occurred along with increased leptin secretion, indicating that during antipsychotic drug treatment the normal inhibitory control of leptin on body weight antipsychotic drug treatment the normal inhibitory control of leptin on body weight is dysfunctional. is dysfunctional.
& & Drug-induced weight gain is not a correlate of symptom improvement, at least in Drug-induced weight gain is not a correlate of symptom improvement, at least in patients in this study receiving risperidone or chlorpromazine. patients in this study receiving risperidone or chlorpromazine.
LIMITATIONS LIMITATIONS
& & The study did not include patients receiving drugs with greatest reported effects The study did not include patients receiving drugs with greatest reported effects (i.e. clozapine and olanzapine) or with minimal effects on weight gain, and thus the (i.e. clozapine and olanzapine) or with minimal effects on weight gain, and thus the findings cannot easily be generalised to all antipsychotic drug treatments. findings cannot easily be generalised to all antipsychotic drug treatments.
& & A relatively small series of patients was studied, limiting the opportunity to A relatively small series of patients was studied, limiting the opportunity to investigate subgroups with adequate statistical power. investigate subgroups with adequate statistical power. Patients were studied for only 10 weeks; whether these findings reach a plateau, continue to increase or even eventually diminish cannot be determined from them. continue to increase or even eventually diminish cannot be determined from them.
